The European Medicines Agency (EMA) has started a fast-track "rolling review" for Revolution Medicines' experimental pill, daraxonrasib, for patients with metastatic pancreatic cancer. The decision follows a late-stage study and addresses a significant unmet need, as these patients have a life expectancy of about six months. The U.S. FDA also granted the drug early access in May 2026.
EMA rolling review process
- ▪The EMA's rolling review process allows its Committee for Medicinal Products for Human Use to evaluate data as it becomes available before a formal marketing application
- ▪The European Medicines Agency (EMA) began a rolling review of Revolution Medicines' experimental drug, daraxonrasib, on July 7, 2026
- ▪While a rolling review can shorten the overall assessment timeline, medicines are held to the same standards as those in a conventional review
Daraxonrasib clinical development
- ▪The EMA's decision to start the review was based on results from a late-stage study comparing daraxonrasib with chemotherapy in previously treated patients
- ▪Daraxonrasib is being studied for metastatic pancreatic ductal adenocarcinoma, a cancer that has spread and for which patients have already received other therapies
Metastatic pancreatic cancer treatment
- ▪The life expectancy for previously treated metastatic pancreatic cancer patients is about six months, according to the EMA
- ▪Patients with metastatic pancreatic cancer whose disease progresses after initial treatment have limited therapeutic options and a poor prognosis
Regulatory fast-track designations
- ▪In May 2026, the U.S. FDA authorized early access to daraxonrasib for patients with previously treated pancreatic cancer
- ▪Daraxonrasib was designated a high-priority medicine under the EMA's Cancer Medicines Pathfinder program
- ▪The EMA's Cancer Medicines Pathfinder program supports treatments that could address significant unmet medical needs
Story comments
Loading comments…